KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Safety and Immunogenicity of a Fourth Dose of Omicron BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18-55 Years Old.

Patricia Winokur, Oyeniyi Diya, David Fitz-Patrick, Michael Dever, Juleen Gayed, Stephen Lockhart, Xia Xu, Ying Zhang, Vishva Bangad, L Tyler Wadsworth, Kevin Cannon, Jose F Cardona, Lisa Usdan, John Ginis, Federico J Mensa, Jing Zou, Xuping Xie, Claire Lu, Sandra Buitrago, Ingrid L Scully, David Cooper, Kenneth Koury, Kathrin U Jansen, Özlem Türeci, Uğur Şahin, Kena A Swanson, William C Gruber, Nicholas Kitchin

Clin Infect Dis 82(5) e1083-e1092

PMID41560517
PMCIDPMC13189652
DOI10.1093/cid/ciag026
发表日期2026-01-21
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other。
摘要

摘要

BACKGROUND: Emergence of severe acute respiratory syndrome coronavirus 2 sublineages warrants the use of sequence-adapted vaccines to provide protection against coronavirus disease 2019. METHODS: In this phase 3 trial, adults 18‒55 years old who had previously received three 30 μg doses of BNT162b2 vaccine were randomized to receive a 60 or 30 μg dose of bivalent Omicron BA.1‒adapted BNT162b2 comprising equal amounts of ancestral and monovalent messenger RNA BA.1 (bivalent BA.1) or a 60 μg dose of monovalent Omicron BA.1‒adapted BNT162b2 (monovalent BA.1). Safety (local reactions, systemic events, adverse events [AEs], and serious AEs) was the primary objective. Exploratory analyses assessed immune responses against Omicron BA.1, BA.4, and BA.5 subvariants and ancestral strain. RESULTS: Among the 1054 randomized participants who received monovalent BA.1 or bivalent BA.1, frequencies of local reactions, systemic events, and AEs were slightly higher with 60 µg monovalent BA.1 than either bivalent BA.1 dose level. One month after vaccination, bivalent BA.1 (30 and 60 μg) and monovalent BA.1 (60 μg) induced substantial neutralizing responses against Omicron BA.1 (50% neutralizing titer geometric mean fold rises [GMFRs], 15.4 [95% CI 12.4-19.2], 17.1 [13.7-21.4], and 24.6 [19.3-31.4], respectively) and ancestral strain (GMFRs, 6.2 [5.1-7.6], 7.3 [6.0-8.9], and 7.0 [5.7-8.7], respectively). In a smaller (n = 30/treatment arm) sentinel cohort, all study vaccines modestly neutralized Omicron BA.4 and BA.5. CONCLUSIONS: Bivalent and monovalent BA.1‒adapted vaccines had a safety profile similar to the original BNT162b2 30 μg and induced substantial neutralizing responses against Omicron BA.1 and ancestral strains. CLINICAL TRIALS REGISTRATION: NCT04955626.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Randomization and administration of a fourth vaccine dose after having previously received three 30 μg doses of the BNT162b2 vaccine for both the sentinel (left) and expanded (right) cohorts. A , Protocol deviations could include receipt of disallowed medication or nonstudy vaccines, or not meeting inclusion/exclusion criteria. B , The reason for withdrawal for 1 participant was classified as “Other.” Participants were recruited from 46 sites in the United States.
非 KM Figure
Figure 2Figure 2. Local reactions ( A ) and systemic events ( B ) reported within 7 d of vaccination in the expanded cohort (safety population). Data are presented for the safety population (all participants who received the study intervention) in the expanded cohort. Severity grading of the specific local reactions and systemic events is provided in Supplementary Table 1. Bars represent the 95% CIs, and numbers above the bars indicate the percentage of participants in each group reporting any severity for the specified event. For antipyretic use, bars represent the percentage of participants who used antipyretics and are therefore not color coded. The bivalent BA.1 60 μg group included participants who received 30 μg BNT162b2-Omi.BA.1 + 30 μg BNT162b (n = 480), the bivalent BA.1 30 μg group included those who received 15 μg BNT162b2-Omi.BA.1 + 15 μg BNT162b2 (n = 158), and the monovalent BA.1 60 μg included those who received 60 μg BNT162b2-Omi.BA.1 (n = 320). Abbreviation: CI, confidence interval.
非 KM Figure
Figure 3Figure 3. SARS-CoV-2 50% neutralization GMTs (95% CI) and GMFRs (95% CI) before and at 1 m after vaccination for the Omicron BA.1 strain in expanded cohort participants without evidence of SARS-CoV-2 infection ( A ), those with or without evidence of SARS-CoV-2 infection and by baseline SARS-CoV-2 status ( B ) (evaluable immunogenicity population). For GMTs and GMFRs, assay results below the LLOQ were set to 0.5 × LLOQ in the analysis. Abbreviations: 1mPD, 1 m postdose; CI, confidence interval; GMFR, geometric mean fold rise; GMT, geometric mean titer; LLOQ, lower limit of quantitation; NT50, 50% neutralizing titer; pre, before vaccination; SARS-CoV-2, severe acute respiratory symdrome coronavirus 2.
非 KM Figure
Figure 4Figure 4. SARS-CoV-2 50% neutralization GMTs (95% CI) and GMFRs (95% CI) before and at 1 m after vaccination for the ancestral strain in expanded cohort participants without evidence of SARS-CoV-2 infection ( A ), those with or without evidence of SARS-CoV-2 infection and by baseline SARS-CoV-2 status ( B ) (evaluable immunogenicity population). For GMTs and GMFRs, assay results below the LLOQ were set to 0.5 × LLOQ in the analysis. Abbreviations: 1mPD, 1 m postdose; CI, confidence interval; GMFR, geometric mean fold rise; GMT, geometric mean titer; LLOQ, lower limit of quantitation; pre, before vaccination; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
非 KM Figure
Figure 5Figure 5. SARS-CoV-2 50% FFRNT GMTs (95% CI) and GMFRs (95% CI) for Omicron BA.1, Omicron BA.4/BA.5, and the ancestral strain in sentinel cohort participants without evidence of SARS-CoV-2 infection from the sentinel cohort (evaluable immunogenicity population). For GMTs and GMFRs, assay results below the LLOQ were set to 0.5 × LLOQ in the analysis. Abbreviations: 1mPD, 1 m postdose; CI, confidence inerval; FFRNT, fluorescent focus reduction neutralization test; GMFR, geometric mean fold rise; GMT, geometric mean titer; LLOQ, lower limit of quantitation; pre, before vaccination; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
非 KM Figure